Latest broker research reports from Joindre Capital Services buy, sell, hold, neutral recommendations along with
share price targets forecast and upside.
- This broker has downgraded this stock from it's previous report. (eg. - Buy->Hold)
- Broker has maintained previous recommendation but reduced share price target.
- This broker has upgraded this stock from it's previous report.(eg. - Sell->Hold)
- Broker has maintained previous recommendation but increased share price target.
Rising Chronic Portfolio to Improve Growth Quality: The company is progressively increasing its penetration of specialty chronic therapies namely cardiology and diabetes. The pivot to chronic therapies would further add to stability in revenues, operating margins, and long-term earnings power on account of high repeat nature of chronic segment prescription and greater brand stickiness. BSV Acquisition Strengthens Specialty Business: Purchase of BSV bolstered the specialty business and led to a significant leap in women's...
Part of Vesuvius plc: Vesuvius plc, a global leader in molten metal flow engineering and advanced metallurgical solutions, has acquired a 75% stake in Foseco Crucible (India) Ltd from the erstwhile parent Morgan Advanced Materials plc through its Indian subsidiary, Foseco India Ltd. Synergy-driven growth potential: Integration with the broader Vesuvius ecosystem will enhance distribution reach, deepen customer penetration, and enable cross-selling opportunities. Market leadership in niche segment: Leading player in the fast-growing...
manufacturing capacity of 5.4GW as of FY26. Established in 1989 and headquartered in Mumbai, the company operates manufacturing facilities across India...
Ceinsys Tech reported Q4FY26 revenue of INR 1,707 Mn, up 19.9% YoY and 0.5% QoQ, driven by a sharp recovery in the Technology Solutions segment that offset weaker execution in the Geospatial business; however, revenue came slightly below our estimate of INR 1,766 Mn. EBITDA stood at INR 402 Mn, up 50.3% YoY and 0.8% QoQ, below our estimate of INR 419 Mn, while EBITDA margin expanded significantly by 477 bps YoY to 23.57% from 18.80% in Q4FY25 and remained largely stable sequentially, improving by 9 bps QoQ, marginally below our...
Revenue: 396 crores, up 7.6% YoY (vs 368 crores), driven by healthy demand across welding consumables and fabrication technology products. EBITDA / Operating Profit: 63 crores, down 4.5% YoY (vs 66 crores), impacted by higher employees and material cost during the quarter....
Lumax auto technologies reported its Q4FY26 numbers, with revenue at Rs. 14,169 Mn (up by 25.07% YoY and 11.51% QoQ), above our estimate of Rs. 12,972 Mn. Gross profit stood at Rs. 5,082 Mn (up by 27.90% YoY and by 12.84% QoQ), above our estimate of Rs. 4,601 Mn. Gross margins expanded by 79 bps YoY and by 42 bps QoQ to 35.9%, above our estimate of 35.5%. EBITDA stood at Rs. 2,032 Mn (up by 29.74% YoY and 15.53% QoQ) above our estimate of Rs. 1,871 Mn, led by reduction in employees cost and other expenses. EBITDA margin increased by 50...
Operating Profit: 675 crores, up 27.8% YoY (vs 528 crores) and 13.8% QoQ (vs 593 crores), driven by strong execution and operating leverage. EBITDA Margin: 30.27% vs 32.57% YoY and 30.63% QoQ; margins remained resilient despite silver, copper and freight cost inflation. Net Profit: 457 crores, up 64.4% YoY (vs 278 crores) and 16.7% QoQ (vs 392 crores), aided by strong profitability and scale benefits. Balance Sheet: Debt/Equity at 0.86x and Debt/EBITDA at 1.4x, maintaining a strong financial profile. Net debt increased due to capex cycle....
Inorganic growth pipeline remains a key long-term catalyst: The company's long-standing capability of acquiring and integrating stressed automotive assets continues to remain a major competitive advantage and an important growth lever. The integration of Atsumitech has progressed well, while acquisitions such as Yutaka Giken and Nexen's automotive harness business are expected to strengthen capabilities across precision machining and global wiring harness operations. Acquisition opportunities remain strong as global OEMs continue consolidating supplier ecosystems and...
Post spin-off advantage: A standalone structure enables sharper strategic focus, more targeted investments, and faster execution. Relaunch-driven recovery: Reintroduced products are accelerating volume growth and aiding market share regain. Significant headroom for market share expansion: Low current market share in large categories offers meaningful expansion potential. Focused strategy to drive volume growth: Increased HCP reach, stronger consumer marketing, and improved distribution to drive volumes....
Domain-Led Acquisitions Strengthen Vertical Capabilities: Acquisitions of Optimum Healthcare and Stratus enhance Infosys' presence in healthcare and insurance, adding deep domain expertise and improving access to high-value, regulated transformation deals. AI-First Strategy Drives Enterprise-Wide Transformation Positioning: Infosys' AI-first framework embeds AI across ~90% of top client engagements, positioning it as an end-to-end enterprise AI orchestrator with strong monetization visibility. Margin Resilience Despite Growth Investments: Operating margins remain...
ESAB India Ltd is the country's leading supplier of welding and cutting products. Incorporated in 1987 and headquartered in Chennai, it is a key subsidiary of the NYSE-listed ESAB Corporation (formerly part of Colfax Corporation), a global leader in fabrication and specialty gas control technology. The company provides a wide array of fabrication and asset-integrity solutions across mission-critical...
Transformational Merger: Creation of a vertically integrated Human + Animal Health platform eliminates internal inefficiencies and builds full value-chain control from intermediates to formulations. Scale & Global Footprint Expansion: Post-merger entity operates 16 manufacturing facilities serving 150+ countries. Strong presence across regulated markets enhances credibility and growth visibility. API & CDMO Entry Boost: Viyash adds strong backend capabilities with USFDA plants and 200+ scientists. Positions the company to benefit from outsourcing...
It is a medical devices company with a product portfolio comprised of 225+ medical devices across 13 specialties including therapy, oncology, anesthesia and respiratory care, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis, central venous access catheters, veterinary medical devices, and others, supported by a robust distribution network of 950+ distributors across India and globally,...
Lumax Mannoh JV Automatic Shift Opportunity: LATL is benefiting from rising automatic transmission penetration, driving higher realizations, strong margins and export potential in its gear shifter JV. High-Margin Tech Play: Lumax's Cornaglia partnership is delivering strong profitability through localisation, lightweight emission products and regulatory tailwinds from fuel efficiency norms. Entry into Alternate Fuels: The Greenfuel deal positions Lumax early in the fast-growing CNG and hydrogen ecosystem, enabling cross-selling to...
Premiumization Through Sunroof Entry: Entry into the sunroof and premium systems segment unlocks higher margin opportunities and strengthens positioning in passenger vehicles. Export Scale-Up Opportunity: Export recovery and 3 growth target by 2030 create diversification benefits and incremental profitability upside. Technology & R&D Moat: Strong patent portfolio, innovation investments,...
Incorporated in April 1995, Premier Energies Limited specializes in manufacturing integrated solar cells and solar panels. Its product portfolio includes solar cells, solar...
Iveco Deal to Drive Global Re-rating: The Iveco acquisition is expected to enhance global scale, provide access to advanced technologies, and strengthen premium positioning beyond India, potentially improving longterm growth visibility and valuation multiples. Demerger Enhancing Structural Strength: A more focused standalone entity with better capital allocation discipline, strong margins, and high ROCE, while improving investor visibility and reducing perceived cyclicality. LCV Share Clawback via Multi-Fuel Play: Supported by improved total...
Acquisition-Led Growth with Strong Integration: Acquisitions to scale faster, enter new technologies, and deepen OEM relationships and proven ability to turn around acquired businesses within a couple of years gives confidence in future value creation. Greenfield Expansion Creating FY27 Growth Visibility: A large number of new plants under execution are backed by customer orders and ramp up...
